Research Article
Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer
Table 4
Summary of pathways returned by REACTOME using DAVID for early- and late-stage NSCLC.
| Early-stage NSCLC | Term | Count | % | value |
| Hemostasis | 6 | 27.3 | | Signaling in immune system | 6 | 27.3 | | Integrin cell surface interactions | 3 | 13.6 | 0.0223 | Metabolism of carbohydrates | 3 | 13.6 | 0.0295 |
| Late-stage NSCLC | Term | Count | % | value |
| Cell cycle, mitotic | 21 | 34.4 | | Cell cycle checkpoints | 10 | 16.4 | | Cdc20: phospho-APC/C-mediated degradation of cyclin A | 6 | 9.8 | | APC-Cdc20-mediated degradation of Nek2A | 4 | 6.6 | 0.00211 | DNA replication | 5 | 8.2 | 0.0239 |
|
|